Assay News and Research

RSS

Abacus Diagnostica's new multiplex assay provides reliable influenza, COVID-19 diagnosis in 75 minutes

Abacus Diagnostica is a small Finnish company developing and manufacturing assays and devices for rapid molecular diagnostics. Since the beginning of COVID-19 outbreak the company has worked decisively on the development of SARS-CoV-2 diagnostics.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Researchers use fruit fly to develop a novel disease model for Pitt-Hopkins syndrome

The researchers from the TalTech molecular neurobiology laboratory headed by professor Tõnis Timmusk used the fruit fly, Drosophila melanogaster to develop a novel disease model for Pitt-Hopkins syndrome (PTHS).

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

BAT study analyzes the toxicological impact of nicotine pouch products

New research by BAT indicates that modern oral products (MOPs) showed lower toxicity responses in certain assays than traditional cigarettes.

28 Sep 2020

Bacteria-free method for making SARS-CoV-2 infectious clones

Using a circular polymerase chain reaction, researchers have developed a method for making severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant virus, with the ability to introduce mutations. The research by Japanese scientists is published on the preprint server bioRxiv* in September 2020.

27 Sep 2020

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

FDA issues emergency use authorization for first serology point-of-care test for COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19.

24 Sep 2020

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

New research being presented at the ESCMID Conference on Coronavirus Disease (ECCVID, online 23-25 September) shows that, in a head-to-head comparison of five tests used to detect SARS-CoV-2 antibodies (known as 'immunoassays'), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results.

24 Sep 2020

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.

23 Sep 2020

Study on domestic cats and dogs in COVID-19+ households

A recent survey conducted by a team of scientists from France reveals that pets living with confirmed coronavirus disease 2019 (COVID-19) patients have a high prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

23 Sep 2020

No discernable difference in SARS-CoV-2 viral loads of young children versus older children and adults

Sharline Madera et al. , in a recent medRxiv* preprint paper, show a detailed investigation of viral nucleic acid among young children and adults, involving over 5,000 cases confirmed by RT-PCR (Reverse Transcriptase – Polymerase Chain Reaction) assay.

23 Sep 2020

UV-C irradiation rapidly inactivates SARS-CoV-2 on surfaces

Researchers at University Hospital Tübingen, Germany, have shown that ultraviolet C (UV-C) irradiation effectively inactivates surface-dried preparations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

SARS-CoV-2 seroprevalence in Swiss schoolchildren shows most infections undiagnosed

A new study reports the seroprevalence among schoolchildren in Zurich, Switzerland. Published on the preprint server medRxiv* in September 2020, this study contributes to the current discussion on how and when to reopen schools.

22 Sep 2020

COVID-19 mitigation efforts significantly decrease influenza activity

The mitigation strategies implemented to curb the spread of COVID-19 appears to reduce the transmission of influenza in the United States, Australia, Chile, and South Africa. These strategies may augment influenza vaccines, especially for high-risk populations during the seasonal influenza transmission.

21 Sep 2020

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Researchers from the NHS Foundation Trust, University of Cambridge and Cambridge Clinical Laboratories have warned that until a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes available, antigen and antibody testing should be carried out among oncology nurses as part of routine patient care.

21 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

Assay News and Research

Abacus Diagnostica's new multiplex assay provides reliable influenza, COVID-19 diagnosis in 75 minutes

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Researchers use fruit fly to develop a novel disease model for Pitt-Hopkins syndrome

SARS-CoV-2 re-infection is real but rare: Case study

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

BAT study analyzes the toxicological impact of nicotine pouch products

Bacteria-free method for making SARS-CoV-2 infectious clones

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

FDA issues emergency use authorization for first serology point-of-care test for COVID-19

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Study on domestic cats and dogs in COVID-19+ households

No discernable difference in SARS-CoV-2 viral loads of young children versus older children and adults

UV-C irradiation rapidly inactivates SARS-CoV-2 on surfaces

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

SARS-CoV-2 seroprevalence in Swiss schoolchildren shows most infections undiagnosed

COVID-19 mitigation efforts significantly decrease influenza activity

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News